|
2008 Journal Article Antibiotic overuse: The influence of social normsBuchman, Timothy G., Dushoff, Jonathan, Effron, Mark B., Ehrlich, Paul R., Fitzpatrick, Susan, Laxminarayan, Ramanan, Levin, Bruce, Levin, Simon A., Lipsitch, Marc, Malani, Anup, Nemeroff, Carol, Otto, Sarah P., Patel, Vimla L. and Solomkin, Joseph S. (2008). Antibiotic overuse: The influence of social norms. Journal of the American College of Surgeons, 207 (2), 265-275. doi: 10.1016/j.jamcollsurg.2008.02.035 |
|
2008 Journal Article Facilitated PCI in patients with ST-elevation myocardial infarctionEllis, Stephen G., Tendera, Michal, de Belder, Mark A., van Boven, Ad J., Widimsky, Petr, Janssens, Luc, Andersen, H. R., Betriu, Amadeo, Savonitto, Stefano, Adamus, Jerzy, Peruga, Jan Z., Kosmider, Maciej, Katz, Olivier, Neunteufl, Thomas, Jorgova, Julia, Dorobantu, Maria, Grinfeld, Liliana, Armstrong, Paul, Brodie, Bruce R., Herrmann, Howard C., Montalescot, Gilles, Neumann, Franz-Josef, Effron, Mark B., Barnathan, Elliot S. and Topol, Eric J. (2008). Facilitated PCI in patients with ST-elevation myocardial infarction. New England Journal of Medicine, 358 (21), 2205-2217. doi: 10.1056/NEJMoa0706816 |
|
2008 Conference Publication One year follow up results of the FINESSE trial of facilitated PCIEllis, Stephen G., Tendera, Michael, De Belder, Mark A., van Boven, Ad J., Widimsky, Petr, Janssens, Luc, Andersen, H. R., Betriu, Amadeo, Savonitto, Stefano, Adamus, Jerzy, Peruga, Jan Z., Kosmider, Maciej, Katz, Olivier, Neunteufl, Thomas, Jorgova, Julia, Dorobantu, Maria, Grinfeld, Liliana, Armstrong, Paul, Brodie, Bruce, Herrmann, Howard C., Montalescot, Gilles, Neumann, Franz-Josef, Effron, Mark B., Barnathan, Elliot S. and Topol, Eric J. (2008). One year follow up results of the FINESSE trial of facilitated PCI. 57th Annual Scientific Session of the American-College-of-Cardiology, Chicago Il, Mar 29-Apr 01, 2008. NEW YORK: ELSEVIER SCIENCE INC. |
|
2008 Journal Article Emergency administration of abciximab for treatment of patients with acute ischemic stroke: Results of an international phase III trial - Abciximab in emergency treatment of stroke trial (AbESTT-II)Adams, Harold P., Effron, Mark B., Torner, James, Davalos, Antoni, Frayne, Judith, Teal, Philip, Leclerc, Jacques, Oemar, Barry, Padgett, Lakshmi, Barnathan, Elliot S. and Hacke, Werner (2008). Emergency administration of abciximab for treatment of patients with acute ischemic stroke: Results of an international phase III trial - Abciximab in emergency treatment of stroke trial (AbESTT-II). Stroke, 39 (1), 87-99. doi: 10.1161/STROKEAHA.106.476648 |
|
2007 Conference Publication The FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial: Results of the formal low molecular weight heparin substudyMontalescot, Gilles, De Belder, Marka A., Janssens, Luc, Andersen, H. R., Pluta, Wladyslaw, Katz, Olivier, Ecollan, Patrick, Sorensen, Vigholt E., Dawkins, Keith D., Miarka, Jacek, De Belder, Adam, Lederballe, Ole, Adgey, Jennifer, Effron, Mark B., Barnathan, Elliot S. and Ellis, Stephen G. (2007). The FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial: Results of the formal low molecular weight heparin substudy. 19th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington Dc, Oct 20-25, 2007. BRIDGEWATER: EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC. |
|
2007 Conference Publication The FINESSE (Facilitated intervention with enhanced reperfusion speed to stop events) trial: Results of the formal low molecular weight heparin substudyMontalescot, Gilles, Ellis, Stephen G., de Belder, Mark A., Janssens, Luc, Andersen, H. R., Pluta, Wladyslaw, Katz, Olivier, Ecollan, Patrick, Sorensen, Vigholt E., Dawkins, Keith D., Miarka, Jacek, de Belder, Adam, Lederballe, Ole, Adgey, Jennifer, Effron, Mark B. and Barnathan, Elliot S. (2007). The FINESSE (Facilitated intervention with enhanced reperfusion speed to stop events) trial: Results of the formal low molecular weight heparin substudy. 19th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington Dc, Oct 20-25, 2007. BRIDGEWATER: EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC. |
|
2005 Conference Publication The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery diseasePatterson, D, Kloner, R, Effron, M, Emmick, J, Bedding, A, Warner, M, Mitchell, M, Braat, S and MacDonald, T (2005). The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. Meeting of the International-Society-for-Sexual-and-Impotence-Research, Montreal Canada, Sep, 2002. OXFORD: BLACKWELL PUBLISHING. doi: 10.1111/j.1365-2125.2005.02479.x |
|
2005 Journal Article Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarctionNikolsky, E, Sadeghi, HM, Effron, MB, Mehran, R, Lansky, AJ, Na, YB, Cox, DA, Garcia, E, Tcheng, JE, Griffin, JJ, Stuckey, TD, Turco, M, Carroll, JD, Grines, CL and Stone, GW (2005). Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. American Journal of Cardiology, 96 (4), 474-481. doi: 10.1016/j.amjcard.2005.04.005 |
|
2004 Conference Publication Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administrationMann, HJ, Demmon, SL, Boelk, DA, Payne, CA, Effron, MB, Rajagopalan, N, Williams, MD, Beck, GM and Gopalrathnam, G (2004). Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration. 38th Midyear Clinical Meeting of the American-Society-of-Health-System-Pharmacists, New Orleans La, Dec 08-09, 2003. BETHESDA: AMER SOC HEALTH-SYSTEM PHARMACISTS. doi: 10.1093/ajhp/61.24.2664 |
|
2004 Conference Publication Safety of drotrecogin alfa (activated): Results of Xeus, a prospective multicenter observational studyKaren, S, Lipsett, P, Effron, M, Rickert, T, Zeckel, M, Linde-Zwirble, W, Steingrub, J and Cheatham, M (2004). Safety of drotrecogin alfa (activated): Results of Xeus, a prospective multicenter observational study. CHEST 2004 Conference, Seattle Wa, Oct 23-28, 2004. NORTHBROOK: AMER COLL CHEST PHYSICIANS. doi: 10.1378/chest.126.4_MeetingAbstracts.724S-a |
|
2004 Conference Publication Clinical use of drotrecogin alfa (activated): Patients treated in the XEUS study differ from high risk prowess patientsRickert, T, Jay, S, Michael, C, Karen, S, Pamela, L, Effron, M, Linde-Zwirble, W and Zeckel, M (2004). Clinical use of drotrecogin alfa (activated): Patients treated in the XEUS study differ from high risk prowess patients. CHEST 2004 Conference, Seattle Wa, Oct 23-28, 2004. NORTHBROOK: AMER COLL CHEST PHYSICIANS. doi: 10.1378/chest.126.4_MeetingAbstracts.865S-a |
|
2004 Journal Article Final results of the ReoPro Readministration RegistryDery, JP, Braden, GA, Lincoff, AM, Kereiakes, DJ, Browne, K, Little, T, George, BS, Sane, DC, Cines, DB, Effron, MB, Mascelli, MA, Langrall, MA, Damaraju, L, Barnathan, ES and Tcheng, JE (2004). Final results of the ReoPro Readministration Registry. American Journal of Cardiology, 93 (8), 979-984. doi: 10.1016/j.amjcard.2003.12.051 |
|
2003 Journal Article Feasibility and implications of an early discharge strategy after percutaneous intervention with Abciximab in acute myocardial infarction (the CADILLAC trial)Kandzari, DE, Tcheng, JE, Cohen, DJ, Bakhai, A, Grines, CL, Cox, DA, Effron, M, Stuckey, T, Griffin, JJ, Turco, M, Carroll, JD, Fahy, M, Mehran, R and Stone, GW (2003). Feasibility and implications of an early discharge strategy after percutaneous intervention with Abciximab in acute myocardial infarction (the CADILLAC trial). American Journal of Cardiology, 92 (7), 779-784. doi: 10.1016/S0002-9149(03)00882-8 |
|
2003 Journal Article Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction - The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trialTcheng, JE, Kandzari, DE, Grines, CL, Cox, DA, Effron, MB, Garcia, E, Griffin, JJ, Guagliumi, G, Stuckey, T, Turco, M, Fahy, M, Lansky, AJ, Mehran, R and Stone, GW (2003). Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction - The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation, 108 (11), 1316-1323. doi: 10.1161/01.CIR.0000087601.45803.86 |
|
2003 Conference Publication Safety of an early discharge strategy following primary intervention with adjunctive glycoprotein IIb/IIIa inhibition: The CADILLAC trialKandzari, DE, Tcheng, JE, Grines, CL, Cohen, DJ, Bakhai, A, Cox, DA, Stuckey, TD, Effron, M, Griffin, JJ, Turco, M, Carroll, JD, Fahy, M, Mehran, R and Stone, GW (2003). Safety of an early discharge strategy following primary intervention with adjunctive glycoprotein IIb/IIIa inhibition: The CADILLAC trial. 52nd Annual Scientific Session of the American-College-of-Cardiology, Chicago Illinois, Mar 30-Apr 02, 2003. NEW YORK: ELSEVIER SCIENCE INC. |
|
2003 Conference Publication Abciximab readministration: Final results of the Reopro(fi) read ministration registryDery, JP, Braden, GA, Lincoff, AM, Kereiakes, DJ, Browne, KF, Little, T, George, BS, Effron, MB, Mascelli, MA, Langrall, MA, Damaraju, L, Barnathan, ES and Tcheng, JE (2003). Abciximab readministration: Final results of the Reopro(fi) read ministration registry. 52nd Annual Scientific Session of the American-College-of-Cardiology, Chicago Illinois, Mar 30-Apr 02, 2003. NEW YORK: ELSEVIER SCIENCE INC. |
|
2003 Conference Publication Benefits and risks of abciximab use in primary Angioplasty for acute myocardial infarction: The CADILLAC trialKandzari, DE, Tcheng, JE, Grines, CL, Effron, M, Cox, DA, Garcia, E, Griffin, JJ, Guagliumi, G, Stuckey, TD, Turco, M, Lansky, AJ, Mehran, R and Stone, GW (2003). Benefits and risks of abciximab use in primary Angioplasty for acute myocardial infarction: The CADILLAC trial. 52nd Annual Scientific Session of the American-College-of-Cardiology, Chicago Illinois, Mar 30-Apr 02, 2003. NEW YORK: ELSEVIER SCIENCE INC. |
|
2002 Conference Publication Cost-effectiveness of coronary stenting and abciximab for patients with AMI: Results from the CADILLAC trialBakhai, A, Stone, GW, Murphy, SA, Githiora, L, Berezin, RH, Gedney, S, Hormel, P, Effron, M, Cox, DA, Tcheng, JE, Grines, CL and Cohen, DJ (2002). Cost-effectiveness of coronary stenting and abciximab for patients with AMI: Results from the CADILLAC trial. American-Heart-Association Abstracts From Scientific Sessions, Chicago Illinois, Nov 17-20, 2002. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2002 Conference Publication Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery diseasePatterson, D, MacDonald, TM, Effron, MB, Emmick, JT, Mitchell, MI and Kloner, RA (2002). Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease. American-Heart-Association Abstracts From Scientific Sessions, Chicago Illinois, Nov 17-20, 2002. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2001 Conference Publication A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical dataKennedy, JS, Bymaster, FP, Schuh, L, Calligaro, DO, Nomikos, G, Felder, CC, Bernauer, M, Kinon, BJ, Baker, RW, Hay, D, Roth, HJ, Dossenbach, M, Kaiser, C, Beasley, CM, Holcombe, JH, Effron, MB and Breier, A (2001). A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. Symposium on Management of Psychoses in Older People, Barcelona Spain, Nov, 2000. W SUSSEX: JOHN WILEY & SONS LTD. doi: 10.1002/1099-1166(200112)16:1+3.0.CO;2-5 |
